Spironolactone oral suspension - CMP Pharma

Drug Profile

Spironolactone oral suspension - CMP Pharma

Alternative Names: CaroSpir

Latest Information Update: 01 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CMP Pharma
  • Class Antihormones; Antihypertensives; Heart failure therapies; Pregnenes; Vascular disorder therapies
  • Mechanism of Action Aldosterone antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperaldosteronism
  • New Molecular Entity No

Highest Development Phases

  • Marketed Heart failure; Hypertension; Oedema

Most Recent Events

  • 30 Oct 2017 Launched for Heart failure in USA (PO)
  • 30 Oct 2017 Launched for Hypertension (Adjunctive treatment) in USA (PO)
  • 30 Oct 2017 Launched for Oedema in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top